ACLX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -766.02% compared to Arcellx's net margin of -49.65%. Arcellx's return on equity of -34.73% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Arcellx has a consensus price target of $111.53, signalling upside risk potential of 80.04%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.23%. Given that Arcellx has higher upside potential than NovaBay Pharmaceuticals, analysts believe Arcellx is more attractive than NovaBay Pharmaceuticals.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $8.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Arcellx's net income of -$62.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Arcellx's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 43.71x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -766.02% compared to Arcellx's net margin of --. Arcellx's return on equity of -34.73% beat Oragenics's return on equity of --.

Arcellx has a consensus price target of $111.53, signalling upside risk potential of 80.04%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Oragenics has higher upside potential than Arcellx, analysts believe Oragenics is more attractive than Arcellx.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $8.1M, which are larger than Oragenics quarterly revenues of --. Arcellx's net income of -$62.3M is lower than Oragenics's net income of -$2.2M. Notably, Arcellx's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 43.71x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -766.02% compared to Arcellx's net margin of -67.73%. Arcellx's return on equity of -34.73% beat Quanterix's return on equity of -14.39%.

Arcellx has a consensus price target of $111.53, signalling upside risk potential of 80.04%. On the other hand Quanterix has an analysts' consensus of $11.25 which suggests that it could grow by 121.24%. Given that Quanterix has higher upside potential than Arcellx, analysts believe Quanterix is more attractive than Arcellx.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Quanterix has a beta of 1.116, suggesting its more volatile than the S&P 500 by 11.641%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $8.1M, which are smaller than Quanterix quarterly revenues of $30.3M. Arcellx's net income of -$62.3M is lower than Quanterix's net income of -$20.5M. Notably, Arcellx's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 43.71x versus 1.46x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -766.02% compared to Arcellx's net margin of --. Arcellx's return on equity of -34.73% beat Theriva Biologics's return on equity of --.

Arcellx has a consensus price target of $111.53, signalling upside risk potential of 80.04%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1438.46%. Given that Theriva Biologics has higher upside potential than Arcellx, analysts believe Theriva Biologics is more attractive than Arcellx.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $8.1M, which are larger than Theriva Biologics quarterly revenues of --. Arcellx's net income of -$62.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, Arcellx's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 43.71x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.